Traders should monitor the AACR presentation on April 20 for updated efficacy data, particularly response rates and durability in Cohort 2 and new data from Cohort 3. While prior results are encouraging, absence of confirmed responses beyond 35% and lack of long-term outcomes may limit near-term catalyst impact.
Price Chart
Executive Summary
Perspective Therapeutics announced that updated clinical data from its [212Pb]VMT-α-NET program for neuroendocrine tumors will be presented at the AACR Annual Meeting 2026. The data, previously shared at ASCO-GI, showed favorable safety and preliminary efficacy signals in early-phase trials, with no dose-limiting toxicities and a 39% response rate in Cohort 2. The upcoming presentation will include additional efficacy data from more patients in Cohort 2 and all of Cohort 3.
Key Facts
- Updated data from the [212Pb]VMT-α-NET program accepted for poster presentation at AACR 2026 on April 20, 2026
- Interim safety data from 56 patients: no dose-limiting toxicities, no treatment-related discontinuations, no serious renal issues
- Grade 3+ adverse events in 37.5% of patients; one transient Grade 4 lymphocyte count decrease, resolved without intervention
- Efficacy data from 25 patients: 76% progression-free at data cutoff; 39% response rate (9/23) in Cohort 2 by investigator assessment, with 35% confirmed responses
- One additional patient showed initial response after prior ESMO 2025 update; follow-up ongoing
- Seven patients showed deepening responses, including one with stable disease
Financial Impact
No financial impact disclosed — this is a clinical development update with no revenue or earnings implications at this stage
Risk Factors
- Clinical data remains preliminary; lack of confirmed responses in all initial responders raises uncertainty
- No pivotal trial results or regulatory filings announced — development path remains early-stage
- Forward-looking statements subject to significant risks including trial delays, funding constraints, and lack of future development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257703 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $1.61 | awaiting T+20 | — | $1.20 (−25.78%) |
Oct 8, 2026 19d ago | 8-K | $2.71 | awaiting T+20 | — | $1.20 (−55.90%) |
Oct 2, 2026 25d ago | Press Release | $2.76 | awaiting T+20 | — | $1.20 (−56.70%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.20 (−59.08%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.20 (−57.47%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.20 (−60.03%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.20 (−61.70%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.20 (−61.70%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.20 (−62.42%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.20 (−60.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers